Substitute Form PT db 440 3 2001

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 12938-002001

Application No. 09/812,945

mation Discourse Statement
Octobro Discourse Statement
(Use several sheets if necessary)

Applicant

Hsuan-Yin Lan-Hargest et al.

Filing Date March 27, 2001 Group Art Unit

(37 CFR §1.98(b))

U.S. Patent Documents Examiner Patent Desig. Filing Date Initial ID Number Patentee Issue Date Class Subclass If Appropriate MM BB5,710,178 01-20-1998 Samid BC 5,705,167 01-06-1998 Bernardon et al. BD 12-09-1997 Chandraratna. 5,696,162 Woodward et al. BE 5,688,819 11-18-1997 BF 5,677,320 10-14-1997 Chandraratna -Nau et al. BG 5,672,746 09-30-1997 BH 5,643,949 07-01-1997 Van Scott et al. BI 5,607,978 03-04-1997 Woodward et al. BJ 5,602,135 02-11-1997 Chandraratna BK 5,547,988 08-20-1996 Yu et al. BL 5,541,155 07-30-1996 Leone-Bay et al. 5,525,629 06-11-1996 Crimmin et al. BM 01-23-1996 Andrews BN 5,486,540 BO 5,475,022 12-12-1995 Chandraratna BP 5,466,718 11-14-1998 Nakatsu et al. 5,420,160 05-30-1995 Gayer et al. BO 5,385,942 01-31-1995 Abe et al. BR 5,369,108 _-11-29-1994 Breslow et al. BS BT 5,320,833 06-14-1994 Deckers et al... BU 5,272,180 12-21-1993 Hashimoto et al. BV5,264,424 11-23-1993 Della Valle et al. BW 5,246,955 09-21-1993 Skibo et al. BX5,244,922 09-14-1993 Burzynski BY 5,235,068 08-10-1993 Minai et al. BZ5,141,959 08-25-1992 Carroll et al. . $\mathsf{C}\mathsf{A}$ Belliotti et al. 5,112,846 05-12-1992 CB 5,091,569 02-25-1992 Matsumoto et al.

Francisco Cinnetons	• V
Examiner Signature /	, // X
/ \	
1 V V G /K	. //
, , ₁ , -	
,	

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form P1 1449 (Modified) RADEMARK

6. Department of Commerce Patent and Trademark Office Attorney's Docket No. 12938-002001

Application No. 09/812,945

Information Disclosure Statement by Applicant (Use several sheets if necessary)

JUL 2 3 2001

Hsuan-Yin Lan-Hargest et al.

Filing Date March 27, 2001

Applicant

Group Art Unit

(37 CFR §1.98(b))

U.S. Patent Documents Examiner Patent Desig. Filing Date Initial Number ID **Issue Date** Patentee Class Subclass If Appropriate CC 02-18-1992 Collins et al. 5,089,524 CD 5,084,214 01-28-1992 Kita et al. CE 12-24-1991 Belliotti et al. 5,075,330 **CF** Mueller et al. 5,064,860 11-12-1991 Hite et al. CG 5,028,629 07-02-1991 01-15-1991 Pettit CH 4,985,436 01-01-1991 Belliotti et al. CI 4,981,865 CJ 4,950,467 08-21-1990 Phalangas et al. CK 4,833,257 05-23-1989 Pettit et al. CL 4,820,828 04-11-1989 Demers et al. CM 4,791,133 12-13-1988 Djuric et al. CN 4,753,934 06-28-1988 Nickl et al. 03-15-1988 Zusi et al. CO 4,731,382 Loev et al. CP 4,722,939 02-02-1988 CQ 4,709,076 11-24-1987 Bombardelli et al. CR 4,699,920 10-13-1987 Skuballa et al. CS 4,638,011 01-20-1987 Das CT 4,623,661 11-18-1986 Summers, Jr. CU 4,621,099 11-04-1986 Loev et al. CV 4,619,945 10-28-1986 Loev et al. CW 4,608,390 08-26-1986 Summers, Jr. CX 4,607,053 08-19-1986 Karanewsky et al. CY 4,605,669 08-12-1986 Summers, Jr. DA 4,604,407 08-05-1986 Haslanger et al. DB 4,564,476 01-14-1986 Ho DC 10-08-1985 Möller et al. 4,545,984 DD 4,534,979 08-13-1985 Loev et al.

Examiner Signature	Date Considered
Mil La	1/6,/0,

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with

next communication to applicant.

Substitute Form PTO 49 (Modified)

Department of Commerce atent and Trademark Office Attorney's Docket No. 12938-002001

Application No. 09/812,945

Group Art Unit

Information Disclosure Statement by Applicant

JUL 2 3 2001

RADEMARY

Applicant Hsuan-Yin Lan-Hargest et al.

(Use several sheets if necessary)

(37 CFR §1.98(b))

Filing Date March 27, 2001

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
Ms	DE	4,505,930	03-19-1985	Loev et al.			
	DF	4,504,494	03-12-1985	Grollier et al.			
	DG	4,472,430	09-18-1984	Loev et al.			
	DH	4,440,940	04-03-1984	Shepherd			
	DI	4,439,443	03-27-1984	Giroux ·			
	DJ	4,388,459	06-14-1983	Shepherd			
	DK	4,371,614	02-01-1983	Anderson et al.			
	DL	4,355,168	10-19-1982	Chiusoli et al.			
	DM	4,335,054	06-15-1982	Blaser et al.			
	DN	4,309,407	01-05-1982	Lautenschläger et al.			
	DO	4,309,357	01-05-1982	Chiusoli et al.			
	DP	4,288,253	09-08-1981	Venable			
	DQ	4,258,057	03-24-1981	Bartmann et al.			
	DR	4,211,783	07-08-1980	Shepherd .			
	DS	4,193,931	03-18-1980	Loeliger			
	DT	4,188,338	02-12-1980	Bruins et al.			
	DU	4,171,318	10-16-1979	Chan et al.			
	DV	4,130,653	12-19-1978	Giroux et al.			
	DW	4,127,723	11-28-1978	Yankee			
	DX	4,127,722	11-28-1978	Lafon			
	DY	4,116,975	09-26-1978	Klaus et al.			
	DZ	4,113,858	09-12-1978	Hashim		-	
	EA	4,081,476	03-28-1978	Anderson et al.			
	EB	4,061,656	12-06-1977	Klaus et al.			
	EC	4,048,332	09-13-1977	Adams et al.		-	
	ED	4,044,149	08-23-1977	Fields et al.			
NR	EE	4,024,182	05-17-1977	Kathawala			

Examiner	Signature	\triangle
----------	-----------	-------------

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PT 9449 (Modified)

U. Department of Commerce Statent and Trademark Office

 $\begin{array}{c} \text{Attorney's Docket No.} \\ 12938\text{-}002001 \end{array}$

Application No. 09/812,945

Information Distribution Statement by Applicant (Use several sheets if necessary)

Applicant

Hsuan-Yin Lan-Hargest et al.

Filing Date

Group Art Unit

(37 CFR §1.98(b))

March 27, 2001

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
Ma	EF	4,011,339	03-08-1977	Galantay et al.			
	EG	3,984,440	10-05-1976	Bollag et al.			
	EH	3,978,100	08-31-1976	Fujita et al.			
	EI	3,909,353	09-30-1975	Tsuchida et al.			
	EJ	3,886,278	05-27-1975	Gallo			
	EK	3,781,314	12-25-1973	Bollag et al.			
	EL	3,755,604	08-28-1973	Gallo			
	EM	3,687,955	08-29-1972	Cerbati et al.			
	EN	3,674,884	07-04-1972	Moritani et al.			
	EO	3,624,127	11-30-71	Shaw et al.			
	EP	3,551,574	12-29-1970	Frohberger et al.			
	EQ	3,479,396	11-18-1969	Buu-Hoi et al.			
	ER	2,840,586	06-24-1958	Inhoffen		-	
W	ES	2,680,755	06-08-1954	Robeson et al.			

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
MA	ET	EP 0 199 151	10-29-1986	European				
	EU	EP 0 161 939	11-21-1985	European				
	EV	WO 01/18171	03-15-2001	WIPO				
Ms	EW	WO 01/38322	05-31-2001	WIPO				

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.			
Initial	ID	Document		
M	EX	Andrews et al., "Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour		
land	LX	cytodifferentiating agents", International Journal for Parasitology, 30, pp. 761-768, (2000).		
w.	EY	Collins et al., "Oral Sodium Phenylbutyrate Therapy in Homozygous & Thalassemia: A Clinical		
Asis	EI	Trial", Blood, Vol. 85, No. 1, pp. 43-49, (1995).		

Examiner Signature	1 /2	Date Considered /10/	
\sim \sim \sim \sim \sim \sim \sim \sim	1	1// •>///	
EXAMINER: Initials citation considere	d. Draw line through citation if r	ot in conformance and not considered.	Include copy of this form with
next communication to applicant.			
		Substi	tute Disclosure Form (PTO-1449)

Substitute Form Rtb-1449 (Modified)

(37 CFR §1.98(b))

S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 12938-002001

Application No. 09/812,945

Information discrete Statement by Applicant (Use several sheets if necessary)

Applicant
Hsuan-Yin Lan-Hargest et al.

t al. Group Art Unit

(Ose several sileets il fiecessary)

Filing Date March 27, 2001

	Other E	Documents (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
MA	EZ	Finnin et al., "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors", Nature, Vol. 401, pp 188-193, (1999).
/	FA	Fruehauf et al., "In Vitro Determination of Drug Response: A Discussion of Clinical Applications", Principles & Practice of Oncology, Vol. 7 No. 12, pp. 1-16, (1993).
	FB	Gore et al., "Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors", Exp. Opin. Invest. Drugs, 9(12), pp. 2923-2934, (2000).
	FC	Hoffman et al., "A non-isotopic assay for histone deacetylase activity", Nucleic Acids Research, Vol. 27, No. 9, pp. 2057-2058, (1999).
	FD	Kemp et al., "Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy", Nature Medicine, Vol. 4, No. 11, pp. 1261-1268, (1998).
	FE	Kim et al., "Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase", Oncogene, Vol. 18, pp. 2461-2470, (1999).
	FF	Marks et al., "Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells", Journal of the National Cancer Institute, Vol. 92, No. 15, pp. 1210-1216, (2000).
	FG	Remiszewski et al., "Synthesis and in Vitro SAR of Straight Chain Hydroxamate Histone Deacetylase Inhibitors", Proceedings of the AACR, Vol. 42, No. 4976, (Feb. 27, 2001).
	FH	Rubenstein et al., "In Vitro Pharmacologic Restoration of CFTR-mediated Chloride Transport with Sodium 4-Phenylbutyrate in Cystic Fibrosis Epithelial Cells Containing ΔF508-CFTR", J. Clin. Invest., Vol. 100, No. 10, pp. 2457-2465, (1997).
	FI	Sandler et al., "Organic Functional Group Preparations", Academic Press, New York and London, Vol. III, pp. 436-437, (1972).
	FJ	Saunders et al., Histone deacetylase inhibitors: novel anticancer agents", Exp. Opin. Invest. Drugs, 8(10), pp. 1611-1621, (1999).
W	FK	Taunton et al., "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p", Science, Vol. 272, pp. 408-411, (1996).

Examiner Signature / /	14	Date Considered
11/1/4		10/

EXAMINER: Initials of fation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.